Zymeworks (NASDAQ:ZYME) Raised to “Strong-Buy” at B. Riley

Zymeworks (NASDAQ:ZYME) was upgraded by stock analysts at B. Riley to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research note on Wednesday. Wall Street Zen raised Zymeworks from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Zymeworks Price Performance

Shares of ZYME opened at $18.06 on Thursday. The business has a 50-day moving average of $15.16. The stock has a market cap of $1.36 billion, a PE ratio of -18.62 and a beta of 1.51. Zymeworks has a 1-year low of $9.03 and a 1-year high of $18.35.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Tuesday, November 8th. The company reported ($1.14) earnings per share for the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%. The business had revenue of $4.40 million for the quarter.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.